Stockhead on MSN
StockTake: First patient joins Tryptamine’s world-first IV psilocin trial for binge-eating disorder
Tryptamine Therapeutics have enrolled the first patient in its world-first intravenous psilocin trial for Binge Eating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback